A hot flash is a discrete neurological event, not just a feeling of warmth; it involves measurable rises in heart rate, skin temperature, and sweating that can be recorded objectively.
The leading explanation is that a cluster of estrogen-sensitive brain cells in the hypothalamus, called KNDy neurons, are normally kept in check by estrogen. When estrogen falls at menopause, these neurons become hyperactive and narrow the body's internal temperature comfort zone, so that small temperature changes trigger a full heat-dissipation response of flushing and sweating.
The KNDy and neurokinin B mechanism is well supported, including direct human proof of concept, and is considered the leading model. The honest caveat is that this is a validated model, not a fully complete account, since blocking this one pathway with a drug reduces but does not eliminate hot flashes for everyone.
What the research shows, and which source each finding rests on
A hot flash is a discrete neurovascular event with measurable rises in heart rate, skin temperature, and sweating, capturable objectively with sternal skin conductance monitoring
Intravenous infusion of neurokinin B induced hot flushes in 8 of 10 healthy premenopausal women, versus 0 of 10 on vehicle (p = 0.0007), direct human proof of concept for the KNDy mechanism
Symptomatic postmenopausal women have an essentially abolished thermoneutral zone, about 0.0 C in women with flashes versus about 0.4 C in asymptomatic women (rectal measurement, p < 0.005), meaning small core temperature elevations trigger full heat-dissipation responses
The leading mechanistic model holds that estrogen-sensitive KNDy neurons (co-expressing kisspeptin, neurokinin B, and dynorphin) in the hypothalamus are normally restrained by estrogen; when estrogen falls, they hypertrophy and become hyperactive, and neurokinin B signaling drives inappropriate heat-dissipation responses
Where the real disagreement is
Each position is shown with its own sources. A position listed here is not necessarily the accepted view.
Strong mechanistic model with a validated but partial effect
The neuroendocrine research consistent across the KNDy model and the neurokinin-3-receptor-antagonist trials
A phase 2 crossover trial of an oral neurokinin-3-receptor antagonist reduced total weekly hot flushes by 45 percentage points more than placebo, which is strong validation of the pathway as a drug target, but also implies a meaningful share of hot flash burden is not fully explained or eliminated by blocking this one receptor.
What would settle it: The core mechanism is already well validated; remaining questions concern individual variability in severity and what other pathways contribute to the portion of symptoms not addressed by blocking this one receptor.
Questions for your doctor
- Is fezolinetant or elinzanetant, the drugs that target this specific brain pathway, an option for me?
- Could something other than menopause be causing my temperature symptoms?
- Would understanding this mechanism change which treatment we choose?
- Are my temperature symptoms affecting me at night specifically, and could that explain my sleep problems too?
Questions with no answer yet
Since blocking the neurokinin B pathway reduces but does not eliminate hot flashes for everyone, what accounts for the portion of hot flash burden this one mechanism does not explain?
Not directly studied yetNo research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.
What is known: The phase 2 trial of an NK3-receptor-blocking drug reduced flashes by 45 percentage points more than placebo, meaning a meaningful share of hot flash frequency persisted even with the pathway blocked, without identifying what other mechanism might account for that remainder.
What would test it: Research into other candidate pathways in women who have residual hot flashes despite NK3 receptor blockade.
Why do some women have an essentially abolished thermoneutral zone while others with similar hormone levels do not, given that the core mechanism is described at a population level?
Not directly studied yetNo research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.
What is known: The thermoneutral-zone finding was drawn from a small physiologic study and describes symptomatic versus asymptomatic groups without explaining what determines which category an individual woman falls into.
What would test it: A larger study directly comparing thermoneutral zone width against individual hormone trajectories and genetic markers to find what predicts symptom severity.
Does the KNDy neuron mechanism operate the same way in every woman, or could there be meaningfully different biological subtypes of hot flashes that respond differently to the same drug target?
Not directly studied yetNo research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.
What is known: The model is well validated at the mechanistic and human proof-of-concept level, but there is no report of research separating potential biological subtypes of hot flashes beyond severity and timing.
What would test it: Biomarker or imaging studies attempting to subtype hot flashes biologically, then testing whether subtype predicts response to NK3-pathway-targeted treatment.
Sources
- 1.Neurokinin B administration induces hot flushes in women.Jayasena CN et al., Sci Rep 2015 · Randomised trial
- 2.Reduced thermoregulatory null zone in postmenopausal women with hot flashes.Freedman RR, Krell W, Am J Obstet Gynecol 1999 · Comparative or small study
- 3.Modulation of body temperature and LH secretion by hypothalamic KNDy (kisspeptin, neurokinin B and dynorphin) neurons: a novel hypothesis on the mechanism of hot flushes.Rance NE et al., Front Neuroendocrinol 2013 · Review, opinion or mechanism
- 4.Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial.Prague JK et al., Lancet 2017 · Randomised trial
The letter grades the type of study behind a claim, not the answer itself.
This page is general information based on published research and public sources. It is not medical advice and not a personal assessment, and it does not replace a conversation with your doctor. Peritale is a wellness product, not a medical device, and is not intended to diagnose, treat, cure or prevent any disease. For any medical question, speak with a licensed clinician.
You are not imagining it
In about seven minutes on your phone, Peritale reads five signal systems and maps your symptoms, so you can see that what you feel is real, follow your hormonal transition over time, and walk into your doctor ready to ask for the care you deserve. Your first check is free, no credit card.
Start Free MappingRelated questions
- How long do hot flashes actually last?
- Are my hot flashes just uncomfortable, or could they be a warning sign about my heart or brain health?
- What is fezolinetant (Veozah) and is it safe to take for hot flashes?
- What is elinzanetant (Lynkuet) and how is it different from fezolinetant?
- Are the new non-hormonal drugs (fezolinetant, elinzanetant) as good as hormone therapy for hot flashes?
- How do I know if a hot flash treatment actually works, versus me just wanting it to work?
- Back to topic: Hot flashes and their treatments